{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T19:04:24Z","timestamp":1788721464274,"version":"build-2803163510"},"reference-count":160,"publisher":"China Science Publishing & Media Ltd.","issue":"6","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2023,6,1]]},"DOI":"10.3724\/abbs.2023101","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T02:03:27Z","timestamp":1685066607000},"page":"974-987","update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["Immunotherapy in leukaemia"],"prefix":"10.3724","volume":"55","author":[{"given":"Xingmei","family":"Mu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chumao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loujie","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaowei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xijie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junke","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"Bray F","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68: 394-424.","journal-title":"CA Cancer J Clin"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1182\/blood-2011-12-379008","volume":"119","author":"Juliusson G","year":"2012","unstructured":"Juliusson G, Lazarevic V, H\u00f6rstedt AS, Hagberg O, H\u00f6glund M. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood, 2012, 119: 3890-3899.","journal-title":"Blood"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"a034819","DOI":"10.1101\/cshperspect.a034819","volume":"10","author":"Bispo JAB","year":"2020","unstructured":"Bispo JAB, Pinheiro PS, Kobetz EK. Epidemiology and etiology of leukemia and lymphoma. Cold Spring Harb Perspect Med, 2020, 10:","journal-title":"Cold Spring Harb Perspect Med"},{"key":"CITATION4","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A,                         et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.                                                      N Engl J Med                          2013,  368: 2059\u20132074.","DOI":"10.1056\/NEJMoa1301689"},{"key":"CITATION5","doi-asserted-by":"crossref","unstructured":"Gratwohl A, Niederwieser D. History of hematopoietic stem cell transplantation: evolution and perspectives.                                                      Curr Probl Dermatol                          2012, 43: 81\u201390.","DOI":"10.1159\/000335266"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","volume":"369","author":"Lo-Coco F","year":"2013","unstructured":"Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med, 2013, 369: 111-121.","journal-title":"N Engl J Med"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"Braun TP","year":"2020","unstructured":"Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell, 2020, 37: 530-542.","journal-title":"Cancer Cell"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3324\/haematol.2019.240747","volume":"106","author":"Burchert A","year":"2021","unstructured":"Burchert A. Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia. Haematologica, 2021, 106: 664-670.","journal-title":"Haematologica"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1101\/gad.349368.122","volume":"36","author":"Bewersdorf JP","year":"2022","unstructured":"Bewersdorf JP, Abdel-Wahab O. Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic. Genes Dev, 2022, 36: 259-277.","journal-title":"Genes Dev"},{"key":"CITATION10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"Park JH","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, Wang X, S\u00e9n\u00e9chal B, Curran KJ, Sauter C. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med, 2018, 378: 449-459.","journal-title":"N Engl J Med"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"Schuster SJ","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, J\u00e4ger U. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med, 2019, 380: 45-56.","journal-title":"N Engl J Med"},{"key":"CITATION12","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","volume":"8","author":"van de Donk NWCJ","year":"2021","unstructured":"van de Donk NWCJ, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematology, 2021, 8: e446-e461.","journal-title":"Lancet Haematology"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.coi.2014.01.010","volume":"27","author":"Parmar S","year":"2014","unstructured":"Parmar S, Ritchie DS. Allogeneic transplantation as anticancer immunotherapy. Curr Opin Immunol, 2014, 27: 38-45.","journal-title":"Curr Opin Immunol"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1182\/asheducation-2013.1.201","volume":"2013","author":"Schiller GJ","year":"2013","unstructured":"Schiller GJ. High-risk acute myelogenous leukemia: treatment today \u2026 and tomorrow. Hematology, 2013, 2013: 201-208.","journal-title":"Hematology"},{"key":"CITATION15","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","volume":"28","author":"Duval M","year":"2010","unstructured":"Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, Kamble R. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol, 2010, 28: 3730-3738.","journal-title":"J Clin Oncol"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.leukres.2006.04.007","volume":"31","author":"Coppage M","year":"2007","unstructured":"Coppage M, Belanger T, Zauderer M, Sahasrabudhe D. In vitro generation of tumor specific T cells that recognize a shared antigen of AML: molecular characterization of TCR genes. Leukemia Res, 2007, 31: 195-202.","journal-title":"Leukemia Res"},{"key":"CITATION17","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"Sadelain M","year":"2017","unstructured":"Sadelain M, Riviere I, Riddell S. Therapeutic T cell engineering. Nature, 2017, 545: 423-431.","journal-title":"Nature"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.leukres.2016.07.009","volume":"49","author":"Farhadfar N","year":"2016","unstructured":"Farhadfar N, Litzow MR. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia. Leukemia Res, 2016, 49: 13-21.","journal-title":"Leukemia Res"},{"key":"CITATION19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/PPO.0000000000000577","volume":"28","author":"Abaza Y","year":"2022","unstructured":"Abaza Y, Fathi AT. Monoclonal antibodies in acute myeloid leukemia\u2014are we there yet?. Cancer J, 2022, 28: 37-42.","journal-title":"Cancer J"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","volume":"562","author":"Deng M","year":"2018","unstructured":"Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, He L. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature, 2018, 562: 605-609.","journal-title":"Nature"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jamaoncol.2018.2091","volume":"4","author":"Kharfan-Dabaja MA","year":"2018","unstructured":"Kharfan-Dabaja MA, Labopin M, Polge E, Nishihori T, Bazarbachi A, Finke J, Stadler M. Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. JAMA Oncol, 2018, 4: 1245-1253.","journal-title":"JAMA Oncol"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","volume":"86","author":"Kolb HJ","year":"1995","unstructured":"Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia [see comments]. Blood, 1995, 86: 2041-2050.","journal-title":"Blood"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1182\/blood.V91.10.3671","volume":"91","author":"Alyea EP","year":"1998","unstructured":"Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C, Collins H. Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood, 1998, 91: 3671-3680.","journal-title":"Blood"},{"key":"CITATION24","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1038\/sj.leu.2403523","volume":"18","author":"Choi SJ","year":"2004","unstructured":"Choi SJ, Lee JH, Lee JH, Kim S, Seol M, Lee YS, Lee JS. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia, 2004, 18: 1789-1797.","journal-title":"Leukemia"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"Papaemmanuil E","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med, 2016, 374: 2209-2221.","journal-title":"N Engl J Med"},{"key":"CITATION26","unstructured":"Finn L, Dalovisio A, Foran J. Older patients with acute myeloid leukemia: treatment challenges and future directions.                                                      Ochsner J                          2017,                         17: 398\u2013404.."},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","volume":"572","author":"Paczulla AM","year":"2019","unstructured":"Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H, Tandler C. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature, 2019, 572: 254-259.","journal-title":"Nature"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","volume":"25","author":"Toffalori C","year":"2019","unstructured":"Toffalori C, Zito L, Gambacorta V, Riba M, Oliveira G, Bucci G, Barcella M. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med, 2019, 25: 603-611.","journal-title":"Nat Med"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/cncr.34566","volume":"129","author":"Zeng Z","year":"2023","unstructured":"Zeng Z, Maiti A, Herbrich S, Cai T, Cavazos A, Manzella T, Ma H. Triple combination targeting methyltransferase, BCL\u20102, and PD\u20101 facilitates antileukemia responses in acute myeloid leukemia. Cancer, 2023, 129: 531-540.","journal-title":"Cancer"},{"key":"CITATION30","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"Lee DW","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA. Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 2014, 124: 188-195.","journal-title":"Blood"},{"key":"CITATION31","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"Teachey DT","year":"2016","unstructured":"Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov, 2016, 6: 664-679.","journal-title":"Cancer Discov"},{"key":"CITATION32","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/ni1102-999","volume":"3","author":"Khong HT","year":"2002","unstructured":"Khong HT, Restifo NP. Natural selection of tumor variants in the generation of \u201ctumor escape\u201d phenotypes. Nat Immunol, 2002, 3: 999-1005.","journal-title":"Nat Immunol"},{"key":"CITATION33","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1182\/blood-2018-10-846824","volume":"133","author":"Zeiser R","year":"2019","unstructured":"Zeiser R, Vago L. Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. Blood, 2019, 133: 1290-1297.","journal-title":"Blood"},{"key":"CITATION34","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","volume":"379","author":"Christopher MJ","year":"2018","unstructured":"Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ, Klco JM. Immune escape of relapsed AML cells after allogeneic transplantation. N Engl J Med, 2018, 379: 2330-2341.","journal-title":"N Engl J Med"},{"key":"CITATION35","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMoa0811036","volume":"361","author":"Vago L","year":"2009","unstructured":"Vago L, Perna SK, Zanussi M, Mazzi B, Barlassina C, Stanghellini MTL, Perrelli NF. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med, 2009, 361: 478-488.","journal-title":"N Engl J Med"},{"key":"CITATION36","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.3389\/fimmu.2020.01710","volume":"11","author":"Dong Y","year":"2020","unstructured":"Dong Y, Han Y, Huang Y, Jiang S, Huang Z, Chen R, Yu Z. PD-L1 is expressed and promotes the expansion of regulatory T cells in acute myeloid leukemia. Front Immunol, 2020, 11:","journal-title":"Front Immunol"},{"key":"CITATION37","doi-asserted-by":"publisher","first-page":"e1792","DOI":"10.1038\/cddis.2015.162","volume":"6","author":"Jiang Y","year":"2015","unstructured":"Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis, 2015, 6:","journal-title":"Cell Death Dis"},{"key":"CITATION38","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000431062","volume":"89","author":"Kikushige Y","year":"2015","unstructured":"Kikushige Y, Miyamoto T. Identification of TIM-3 as a leukemic stem cell surface molecule in primary acute myeloid leukemia. Oncology, 2015, 89: 28-32.","journal-title":"Oncology"},{"key":"CITATION39","doi-asserted-by":"publisher","first-page":"e1195535","DOI":"10.1080\/2162402X.2016.1195535","volume":"5","author":"Gon\u00e7alves Silva I","year":"2016","unstructured":"Gon\u00e7alves Silva I, R\u00fcegg L, Gibbs BF, Bardelli M, Fruehwirth A, Varani L, Berger SM. The immune receptor Tim-3 acts as a trafficker in a Tim-3\/galectin-9 autocrine loop in human myeloid leukemia cells. OncoImmunology, 2016, 5:","journal-title":"OncoImmunology"},{"key":"CITATION40","doi-asserted-by":"publisher","first-page":"753677","DOI":"10.3389\/fonc.2021.753677","volume":"11","author":"Rezaei M","year":"2021","unstructured":"Rezaei M, Tan J, Zeng C, Li Y, Ganjalikhani-Hakemi M. TIM-3 in leukemia; immune response and beyond. Front Oncol, 2021, 11:","journal-title":"Front Oncol"},{"key":"CITATION41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-015-0134-4","volume":"8","author":"Folgiero V","year":"2015","unstructured":"Folgiero V, Cifaldi L, Pira GL, Goffredo BM, Vinti L, Locatelli F. TIM-3\/Gal-9 interaction induces IFN\u03b3-dependent IDO1 expression in acute myeloid leukemia blast cells. J Hematol Oncol, 2015, 8:","journal-title":"J Hematol Oncol"},{"key":"CITATION42","doi-asserted-by":"publisher","first-page":"57811","DOI":"10.18632\/oncotarget.11063","volume":"7","author":"Darwish NHE","year":"2016","unstructured":"Darwish NHE, Sudha T, Godugu K, Elbaz O, Abdelghaffar HA, Hassan EEA, Mousa SA. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1. Oncotarget, 2016, 7: 57811-57820.","journal-title":"Oncotarget"},{"key":"CITATION43","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1038\/bcj.2015.58","volume":"5","author":"Kong Y","year":"2015","unstructured":"Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Zhu L, Zeng H. PD-1hiTIM-3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J, 2015, 5:","journal-title":"Blood Cancer J"},{"key":"CITATION44","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3892\/ol.2021.12587","volume":"21","author":"Kamal A","year":"2021","unstructured":"Kamal A, Nabih N, Elleboudy N, Radwan S. Expression of immune check point gene TIM\u20113 in patients newly diagnosed with acute myeloid leukemia: significance and impact on outcome. Oncol Lett, 2021, 21:","journal-title":"Oncol Lett"},{"key":"CITATION45","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/cei.13407","volume":"200","author":"Harjunp\u00e4\u00e4 H","year":"2020","unstructured":"Harjunp\u00e4\u00e4 H, Guillerey C. TIGIT as an emerging immune checkpoint. Clin Exp Immunol, 2020, 200: 108-119.","journal-title":"Clin Exp Immunol"},{"key":"CITATION46","doi-asserted-by":"publisher","first-page":"e000957","DOI":"10.1136\/jitc-2020-000957","volume":"8","author":"Chauvin JM","year":"2020","unstructured":"Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer, 2020, 8:","journal-title":"J Immunother Cancer"},{"key":"CITATION47","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.clim.2017.08.021","volume":"190","author":"Wang M","year":"2018","unstructured":"Wang M, Bu J, Zhou M, Sido J, Lin Y, Liu G, Lin Q. CD8 + T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients. Clin Immunol, 2018, 190: 64-73.","journal-title":"Clin Immunol"},{"key":"CITATION48","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-15-2626","volume":"22","author":"Kong Y","year":"2016","unstructured":"Kong Y, Zhu L, Schell TD, Zhang J, Claxton DF, Ehmann WC, Rybka WB. T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients. Clin Cancer Res, 2016, 22: 3057-3066.","journal-title":"Clin Cancer Res"},{"key":"CITATION49","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1007\/s00335-018-9770-7","volume":"29","author":"Stamm H","year":"2018","unstructured":"Stamm H, Wellbrock J, Fiedler W. Interaction of PVR\/PVRL2 with TIGIT\/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer. Mamm Genome, 2018, 29: 694-702.","journal-title":"Mamm Genome"},{"key":"CITATION50","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/imcb.1003","volume":"96","author":"Sasidharan Nair V","year":"2018","unstructured":"Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. Immunol Cell Biol, 2018, 96: 21-33.","journal-title":"Immunol Cell Biol"},{"key":"CITATION51","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1111\/ajco.13236","volume":"16","author":"Chen Y","year":"2020","unstructured":"Chen Y, Tan J, Huang S, Huang X, Huang J, Chen J, Yu Z. Higher frequency of the CTLA\u20104                         + LAG\u20103                         + T\u2010cell subset in patients with newly diagnosed acute myeloid leukemia. Asia\u2010Pac J Clin Oncol, 2020, 16:","journal-title":"Asia\u2010Pac J Clin Oncol"},{"key":"CITATION52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/tan.13872","volume":"96","author":"Radwan SM","year":"2020","unstructured":"Radwan SM, Elleboudy NS, Nabih NA, Kamal AM. The immune checkpoints cytotoxic T lymphocyte antigen\u20104 and Lymphocyte activation gene\u20103 expression is up\u2010regulated in acute myeloid leukemia. HLA, 2020, 96: 3-12.","journal-title":"HLA"},{"key":"CITATION53","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/(SICI)1521-4141(199801)28:01<90::AID-IMMU90>3.0.CO;2-5","volume":"28","author":"Costello RT","year":"1998","unstructured":"Costello RT, Mallet F, Sainty D, Maraninchi D, Gastaut JA, Olive D. Regulation of CD80\/B7-1 and CD86\/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition. Eur J Immunol, 1998, 28: 90-103.","journal-title":"Eur J Immunol"},{"key":"CITATION54","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"Majeti R","year":"2009","unstructured":"Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs Jr. KD, van Rooijen N. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell, 2009, 138: 286-299.","journal-title":"Cell"},{"key":"CITATION55","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3389\/fonc.2019.01380","volume":"9","author":"Chao MP","year":"2019","unstructured":"Chao MP, Takimoto CH, Feng DD, McKenna K, Gip P, Liu J, Volkmer JP. Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies. Front Oncol, 2019, 9:","journal-title":"Front Oncol"},{"key":"CITATION56","doi-asserted-by":"publisher","first-page":"5832","DOI":"10.1182\/blood-2011-11-391722","volume":"119","author":"Aurelius J","year":"2012","unstructured":"Aurelius J, Thor\u00e9n FB, Akhiani AA, Brune M, Palmqvist L, Hansson M, Hellstrand K. Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase\/gp91phox expression and the PARP-1\/PAR pathway of apoptosis. Blood, 2012, 119: 5832-5837.","journal-title":"Blood"},{"key":"CITATION57","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/blood-2005-08-027979","volume":"109","author":"Fauriat C","year":"2007","unstructured":"Fauriat C, Just-Landi S, Mallet F\u0327, Arnoulet C, Sainty D, Olive D, Costello RT. Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood, 2007, 109: 323-330.","journal-title":"Blood"},{"key":"CITATION58","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/gene.2014.58","volume":"16","author":"Baraga\u00f1o Raneros A","year":"2015","unstructured":"Baraga\u00f1o Raneros A, Mart\u00edn-Palanco V, Fernandez AF, Rodriguez RM, Fraga MF, Lopez-Larrea C, Suarez-Alvarez B. Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia. Genes Immun, 2015, 16: 71-82.","journal-title":"Genes Immun"},{"key":"CITATION59","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/icb.2011.15","volume":"90","author":"Sanchez\u2010Correa B","year":"2012","unstructured":"Sanchez\u2010Correa B, Gayoso I, Bergua JM, Casado JG, Morgado S, Solana R, Tarazona R. Decreased expression of DNAM\u20101 on NK cells from acute myeloid leukemia patients. Immunol Cell Biol, 2012, 90: 109-115.","journal-title":"Immunol Cell Biol"},{"key":"CITATION60","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1182\/blood-2013-09-526590","volume":"123","author":"Elias S","year":"2014","unstructured":"Elias S, Yamin R, Golomb L, Tsukerman P, Stanietsky-Kaynan N, Ben-Yehuda D, Mandelboim O. Immune evasion by oncogenic proteins of acute myeloid leukemia. Blood, 2014, 123: 1535-1543.","journal-title":"Blood"},{"key":"CITATION61","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/83713","volume":"27","author":"Bennett CL","year":"2001","unstructured":"Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet, 2001, 27: 20-21.","journal-title":"Nat Genet"},{"key":"CITATION62","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/83784","volume":"27","author":"Brunkow ME","year":"2001","unstructured":"Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE. Disruption of a new forkhead\/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet, 2001, 27: 68-73.","journal-title":"Nat Genet"},{"key":"CITATION63","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/ni1536","volume":"8","author":"Pandiyan P","year":"2007","unstructured":"Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation\u2013mediated apoptosis of effector CD4+ T cells. Nat Immunol, 2007, 8: 1353-1362.","journal-title":"Nat Immunol"},{"key":"CITATION64","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nature06306","volume":"450","author":"Collison LW","year":"2007","unstructured":"Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature, 2007, 450: 566-569.","journal-title":"Nature"},{"key":"CITATION65","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1084\/jem.20062512","volume":"204","author":"Deaglio S","year":"2007","unstructured":"Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med, 2007, 204: 1257-1265.","journal-title":"J Exp Med"},{"key":"CITATION66","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","volume":"21","author":"Huang CT","year":"2004","unstructured":"Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL. Role of LAG-3 in regulatory T cells. Immunity, 2004, 21: 503-513.","journal-title":"Immunity"},{"key":"CITATION67","doi-asserted-by":"publisher","first-page":"5916","DOI":"10.4049\/jimmunol.180.9.5916","volume":"180","author":"Liang B","year":"2008","unstructured":"Liang B, Workman C, Lee J, Chew C, Dale BM, Colonna L, Flores M. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol, 2008, 180: 5916-5926.","journal-title":"J Immunol"},{"key":"CITATION68","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","volume":"322","author":"Wing K","year":"2008","unstructured":"Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T. CTLA-4 Control over Foxp3                         + regulatory T cell function. Science, 2008, 322: 271-275.","journal-title":"Science"},{"key":"CITATION69","doi-asserted-by":"publisher","first-page":"e140242","DOI":"10.1172\/JCI140242","volume":"131","author":"He X","year":"2021","unstructured":"He X, Wan J, Yang X, Zhang X, Huang D, Li X, Zou Y. Bone marrow niche ATP levels determine leukemia-initiating cell activity via P2X7 in leukemic models. J Clin Invest, 2021, 131:","journal-title":"J Clin Invest"},{"key":"CITATION70","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1158\/1078-0432.CCR-08-3010","volume":"15","author":"Szczepanski MJ","year":"2009","unstructured":"Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A, Foon KA. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res, 2009, 15: 3325-3332.","journal-title":"Clin Cancer Res"},{"key":"CITATION71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/9325261","volume":"2018","author":"Delia M","year":"2018","unstructured":"Delia M, Carluccio P, Mestice A, Brunetti C, Albano F, Specchia G. Impact of bone marrow aspirate tregs on the response rate of younger newly diagnosed acute myeloid leukemia patients. J Immunol Res, 2018, 2018: 1-7.","journal-title":"J Immunol Res"},{"key":"CITATION72","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.3389\/fimmu.2020.01371","volume":"11","author":"Yang Y","year":"2020","unstructured":"Yang Y, Li C, Liu T, Dai X, Bazhin AV. Myeloid-derived suppressor cells in tumors: from mechanisms to antigen specificity and microenvironmental regulation. Front Immunol, 2020, 11:","journal-title":"Front Immunol"},{"key":"CITATION73","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s12185-015-1865-2","volume":"102","author":"Sun H","year":"2015","unstructured":"Sun H, Li Y, Zhang Z, Ju Y, Li L, Zhang B, Liu B. Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia. Int J Hematol, 2015, 102: 579-586.","journal-title":"Int J Hematol"},{"key":"CITATION74","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1182\/blood-2016-07-730614","volume":"129","author":"Pyzer AR","year":"2017","unstructured":"Pyzer AR, Stroopinsky D, Rajabi H, Washington A, Tagde A, Coll M, Fung J. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood, 2017, 129: 1791-1801.","journal-title":"Blood"},{"key":"CITATION75","doi-asserted-by":"publisher","first-page":"230","DOI":"10.4274\/tjh.galenos.2022.2022.0137","volume":"39","author":"Ren X","year":"2022","unstructured":"Ren X, Tao Q, Wang H, Zhang Q, Zhou M, Liu L, Zhai Z. Monocytic myeloid-derived suppressor cells but not monocytes predict poor prognosis of acute myeloid leukemia. Turk J haematol, 2022, 39: 230-236.","journal-title":"Turk J haematol"},{"key":"CITATION76","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/cncr.31896","volume":"125","author":"Williams P","year":"2019","unstructured":"Williams P, Basu S, Garcia\u2010Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F. The distribution of T\u2010cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer, 2019, 125: 1470-1481.","journal-title":"Cancer"},{"key":"CITATION77","doi-asserted-by":"publisher","first-page":"e1062208","DOI":"10.1080\/2162402X.2015.1062208","volume":"5","author":"Kittang AO","year":"2016","unstructured":"Kittang AO, Kordasti S, Sand KE, Costantini B, Kramer AM, Perezabellan P, Seidl T. Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome. OncoImmunology, 2016, 5:","journal-title":"OncoImmunology"},{"key":"CITATION78","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","volume":"23","author":"Mantovani A","year":"2002","unstructured":"Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol, 2002, 23: 549-555.","journal-title":"Trends Immunol"},{"key":"CITATION79","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1159\/000500315","volume":"143","author":"Li Y","year":"2020","unstructured":"Li Y, You MJ, Yang Y, Hu D, Tian C. The Role of tumor-associated macrophages in leukemia. Acta Haematol, 2020, 143: 112-117.","journal-title":"Acta Haematol"},{"key":"CITATION80","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","volume":"36","author":"Tettamanti S","year":"2022","unstructured":"Tettamanti S, Pievani A, Biondi A, Dotti G, Serafini M. Catch me if you can: how AML and its niche escape immunotherapy. Leukemia, 2022, 36: 13-22.","journal-title":"Leukemia"},{"key":"CITATION81","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1182\/blood-2006-07-036863","volume":"109","author":"Curti A","year":"2007","unstructured":"Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E, Salvestrini V. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25                         \u2212 into CD25                         + T regulatory cells. Blood, 2007, 109: 2871-2877.","journal-title":"Blood"},{"key":"CITATION82","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1182\/blood-2013-01-480129","volume":"122","author":"Mussai F","year":"2013","unstructured":"Mussai F, De Santo C, Abu-Dayyeh I, Booth S, Quek L, McEwen-Smith RM, Qureshi A. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood, 2013, 122: 749-758.","journal-title":"Blood"},{"key":"CITATION83","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fonc.2020.00155","volume":"10","author":"Tabe Y","year":"2020","unstructured":"Tabe Y, Konopleva M, Andreeff M. Fatty acid metabolism, bone marrow adipocytes, and AML. Front Oncol, 2020, 10:","journal-title":"Front Oncol"},{"key":"CITATION84","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.stem.2016.06.001","volume":"19","author":"Ye H","year":"2016","unstructured":"Ye H, Adane B, Khan N, Sullivan T, Minhajuddin M, Gasparetto M, Stevens B. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche. Cell Stem Cell, 2016, 19: 23-37.","journal-title":"Cell Stem Cell"},{"key":"CITATION85","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.4049\/jimmunol.1003613","volume":"186","author":"Michalek RD","year":"2011","unstructured":"Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, Sullivan SA. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol, 2011, 186: 3299-3303.","journal-title":"J Immunol"},{"key":"CITATION86","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1182\/blood.V89.4.1405","volume":"89","author":"Inoue K","year":"1997","unstructured":"Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y, Miyake S. Aberrant overexpression of the wilms tumor gene (WT1) in human leukemia. Blood, 1997, 89: 1405-1412.","journal-title":"Blood"},{"key":"CITATION87","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1172\/JCI97482","volume":"129","author":"van der Lee DI","year":"2019","unstructured":"van der Lee DI, Reijmers RM, Honders MW, Hagedoorn RS, de Jong RCM, Kester MGD, van der Steen DM. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia. J Clin Invest, 2019, 129: 774-785.","journal-title":"J Clin Invest"},{"key":"CITATION88","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/leu.2012.145","volume":"26","author":"Anguille S","year":"2012","unstructured":"Anguille S, Van Tendeloo VF, Berneman ZN. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia, 2012, 26: 2186-2196.","journal-title":"Leukemia"},{"key":"CITATION89","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/leu.2014.62","volume":"28","author":"Pizzitola I","year":"2014","unstructured":"Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, Lassailly F, Tettamanti S, Spinelli O, Biondi A. Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia, 2014, 28: 1596-1605.","journal-title":"Leukemia"},{"key":"CITATION90","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/leu.2015.52","volume":"29","author":"Kenderian SS","year":"2015","unstructured":"Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJD, Scholler J. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia, 2015, 29: 1637-1647.","journal-title":"Leukemia"},{"key":"CITATION91","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","volume":"123","author":"Gill S","year":"2014","unstructured":"Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor\u2013modified T cells. Blood, 2014, 123: 2343-2354.","journal-title":"Blood"},{"key":"CITATION92","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","volume":"32","author":"Perna F","year":"2017","unstructured":"Perna F, Berman SH, Soni RK, Mansilla-Soto J, Eyquem J, Hamieh M, Hendrickson RC. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell, 2017, 32: 506-519.e5.","journal-title":"Cancer Cell"},{"key":"CITATION93","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","volume":"33","author":"Haubner S","year":"2019","unstructured":"Haubner S, Perna F, K\u00f6hnke T, Schmidt C, Berman S, Augsberger C, Schnorfeil FM. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia, 2019, 33: 64-74.","journal-title":"Leukemia"},{"key":"CITATION94","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/neup.12222","volume":"35","author":"Satoh J","year":"2015","unstructured":"Satoh J, Kino Y, Motohashi N, Ishida T, Yagishita S, Jinnai K, Arai N. Immunohistochemical characterization of CD33 expression on microglia in Nasu-Hakola disease brains. Neuropathology, 2015, 35: 529-537.","journal-title":"Neuropathology"},{"key":"CITATION95","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s11899-017-0425-7","volume":"12","author":"Pemmaraju N","year":"2017","unstructured":"Pemmaraju N. Novel pathways and potential therapeutic strategies for blastic plasmacytoid dendritic cell neoplasm (BPDCN): CD123 and beyond. Curr Hematol Malig Rep, 2017, 12: 510-512.","journal-title":"Curr Hematol Malig Rep"},{"key":"CITATION96","doi-asserted-by":"publisher","first-page":"8443","DOI":"10.1158\/0008-5472.CAN-04-1659","volume":"64","author":"Bakker ABH","year":"2004","unstructured":"Bakker ABH, van den Oudenrijn S, Bakker AQ, Feller N, van Meijer M, Bia JA, Jongeneelen MAC. C-type lectin-like molecule-1. Cancer Res, 2004, 64: 8443-8450.","journal-title":"Cancer Res"},{"key":"CITATION97","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1172\/JCI129204","volume":"130","author":"Vago L","year":"2020","unstructured":"Vago L, Gojo I. Immune escape and immunotherapy of acute myeloid leukemia. J Clin Invest, 2020, 130: 1552-1564.","journal-title":"J Clin Invest"},{"key":"CITATION98","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/gt.2010.21","volume":"17","author":"Peinert S","year":"2010","unstructured":"Peinert S, Prince HM, Guru PM, Kershaw MH, Smyth MJ, Trapani JA, Gambell P. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Ther, 2010, 17: 678-686.","journal-title":"Gene Ther"},{"key":"CITATION99","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ymthe.2018.10.001","volume":"27","author":"Gomes-Silva D","year":"2019","unstructured":"Gomes-Silva D, Atilla E, Atilla PA, Mo F, Tashiro H, Srinivasan M, Lulla P. CD7 CAR T cells for the therapy of acute myeloid leukemia. Mol Ther, 2019, 27: 272-280.","journal-title":"Mol Ther"},{"key":"CITATION100","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.ejca.2009.02.021","volume":"45","author":"Terwijn M","year":"2009","unstructured":"Terwijn M, Feller N, van Rhenen A, Kelder A, Westra G, Zweegman S, Ossenkoppele G. Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. Eur J Cancer, 2009, 45: 1692-1699.","journal-title":"Eur J Cancer"},{"key":"CITATION101","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","volume":"122","author":"Casucci M","year":"2013","unstructured":"Casucci M, Nicolis di Robilant B, Falcone L, Camisa B, Norelli M, Genovese P, Gentner B. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood, 2013, 122: 3461-3472.","journal-title":"Blood"},{"key":"CITATION102","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/nm1483","volume":"12","author":"Jin L","year":"2006","unstructured":"Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med, 2006, 12: 1167-1174.","journal-title":"Nat Med"},{"key":"CITATION103","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3324\/haematol.2017.186346","volume":"103","author":"Ciurea SO","year":"2018","unstructured":"Ciurea SO. Allogeneic stem cell transplantation for FLT3 mutated acute myeloid leukemia in first complete remission: does age really matter?. Haematologica, 2018, 103: 191-193.","journal-title":"Haematologica"},{"key":"CITATION104","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1182\/blood.2020008221","volume":"138","author":"Sauer T","year":"2021","unstructured":"Sauer T, Parikh K, Sharma S, Omer B, Sedloev D, Chen Q, Angenendt L. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood, 2021, 138: 318-330.","journal-title":"Blood"},{"key":"CITATION105","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1038\/s41375-020-0818-9","volume":"34","author":"Myburgh R","year":"2020","unstructured":"Myburgh R, Kiefer JD, Russkamp NF, Magnani CF, Nu\u00f1ez N, Simonis A, Pfister S. Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells. Leukemia, 2020, 34: 2688-2703.","journal-title":"Leukemia"},{"key":"CITATION106","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1182\/blood.2020009192","volume":"138","author":"Jetani H","year":"2021","unstructured":"Jetani H, Navarro-Bail\u00f3n A, Maucher M, Frenz S, Verbruggen C, Yeguas A, Vidriales MB. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. Blood, 2021, 138: 1830-1842.","journal-title":"Blood"},{"key":"CITATION107","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"Stone RM","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a                         FLT3 Mutation. N Engl J Med, 2017, 377: 454-464.","journal-title":"N Engl J Med"},{"key":"CITATION108","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","volume":"20","author":"Cortes JE","year":"2019","unstructured":"Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, Kr\u00e4mer A. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol, 2019, 20: 984-997.","journal-title":"Lancet Oncol"},{"key":"CITATION109","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1080\/1042819042000206687","volume":"45","author":"Gadhoum Z","year":"2004","unstructured":"Gadhoum Z, Delaunay J, Maquarre E, Durand L, Lancereaux V, Qi J, Robert-Lezenes J. The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells. Leukemia Lymphoma, 2004, 45: 1501-1510.","journal-title":"Leukemia Lymphoma"},{"key":"CITATION110","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1182\/blood.V99.1.290","volume":"99","author":"Charrad RS","year":"2002","unstructured":"Charrad RS, Gadhoum Z, Qi J, Glachant A, Allouche M\u0300, Jasmin C, Chomienne C. Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines. Blood, 2002, 99: 290-299.","journal-title":"Blood"},{"key":"CITATION111","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12943-016-0571-x","volume":"16","author":"Siveen KS","year":"2017","unstructured":"Siveen KS, Uddin S, Mohammad RM. Targeting acute myeloid leukemia stem cell signaling by natural products. Mol Cancer, 2017, 16:","journal-title":"Mol Cancer"},{"key":"CITATION112","doi-asserted-by":"publisher","first-page":"5059","DOI":"10.3390\/ijms22105059","volume":"22","author":"Yang W","year":"2021","unstructured":"Yang W, Kim D, Kim DK, Choi KU, Suh DS, Kim JH. Therapeutic strategies for targeting ovarian cancer stem cells. Int J Mol Sci, 2021, 22:","journal-title":"Int J Mol Sci"},{"key":"CITATION113","doi-asserted-by":"publisher","first-page":"473","DOI":"10.4252\/wjsc.v6.i4.473","volume":"6","author":"Zhou J","year":"2014","unstructured":"Zhou J, Chng WJ. Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia. World J Stem Cells, 2014, 6:","journal-title":"World J Stem Cells"},{"key":"CITATION114","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1172\/JCI93198","volume":"128","author":"Zhang Y","year":"2018","unstructured":"Zhang Y, Xia F, Liu X, Yu Z, Xie L, Liu L, Chen C. JAM3 maintains leukemia-initiating cell self-renewal through LRP5\/AKT\/\u03b2-catenin\/CCND1 signaling. J Clin Invest, 2018, 128: 1737-1751.","journal-title":"J Clin Invest"},{"key":"CITATION115","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3324\/haematol.2016.151555","volume":"102","author":"Zhang F","year":"2017","unstructured":"Zhang F, Liu X, Chen C, Zhu J, Yu Z, Xie J, Xie L. CD244 maintains the proliferation ability of leukemia initiating cells through SHP-2\/p27                         kip1 signaling. Haematologica, 2017, 102: 707-718.","journal-title":"Haematologica"},{"key":"CITATION116","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-01684-0","author":"Gottschlich A","year":"2023, doi: 10.1038\/s41587-023-01684-0","unstructured":"Gottschlich A, Thomas M, Gr\u00fcnmeier R, Lesch S, Rohrbacher L, Igl V, Briukhovetska D. Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. Nat Biotechnol, 2023, doi: 10.1038\/s41587-023-01684-0,","journal-title":"Nat Biotechnol"},{"key":"CITATION117","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/sj.leu.2404624","volume":"21","author":"Yang L","year":"2007","unstructured":"Yang L, Han Y, Saurez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia, 2007, 21: 868-876.","journal-title":"Leukemia"},{"key":"CITATION118","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1634\/theoncologist.2011-0240","volume":"17","author":"Van Driessche A","year":"2012","unstructured":"Van Driessche A, Berneman ZN, Van Tendeloo VFI. Active specific immunotherapy targeting the Wilms\u2019 tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist, 2012, 17: 250-259.","journal-title":"Oncologist"},{"key":"CITATION119","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1182\/blood.2020010477","volume":"138","author":"Augsberger C","year":"2021","unstructured":"Augsberger C, H\u00e4nel G, Xu W, Pulko V, Hanisch LJ, Augustin A, Challier J. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody. Blood, 2021, 138: 2655-2669.","journal-title":"Blood"},{"key":"CITATION120","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"Cheever MA","year":"2009","unstructured":"Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res, 2009, 15: 5323-5337.","journal-title":"Clin Cancer Res"},{"key":"CITATION121","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1182\/blood-2006-07-032839","volume":"109","author":"Graf C","year":"2007","unstructured":"Graf C, Heidel F, Tenzer S, Radsak MP, Solem FK, Britten CM, Huber C. A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells. Blood, 2007, 109: 2985-2988.","journal-title":"Blood"},{"key":"CITATION122","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1182\/blood-2011-11-394395","volume":"120","author":"Greiner J","year":"2012","unstructured":"Greiner J, Ono Y, Hofmann S, Schmitt A, Mehring E, G\u00f6tz M, Guillaume P. Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia. Blood, 2012, 120: 1282-1289.","journal-title":"Blood"},{"key":"CITATION123","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.drup.2009.06.001","volume":"12","author":"Konopleva M","year":"2009","unstructured":"Konopleva M, Tabe Y, Zeng Z, Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resistance Updates, 2009, 12: 103-113.","journal-title":"Drug Resistance Updates"},{"key":"CITATION124","doi-asserted-by":"publisher","first-page":"6206","DOI":"10.1182\/blood-2008-06-162123","volume":"113","author":"Nervi B","year":"2009","unstructured":"Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, Prior JL. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood, 2009, 113: 6206-6214.","journal-title":"Blood"},{"key":"CITATION125","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1365-2141.2007.06590.x","volume":"137","author":"Burger JA","year":"2007","unstructured":"Burger JA, B\u00fcrkle A. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol, 2007, 137: 288-296.","journal-title":"Br J Haematol"},{"key":"CITATION126","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1051\/jbio\/2010022","volume":"204","author":"Biajoux V","year":"2010","unstructured":"Biajoux V, Bignon A, Bouchet-Delbos L, \u00c9milie D, Balabanian K. Dysfunctions of the CXCL12 (SDF-1)\/CXCR4 signaling axis in the WHIM syndrome and the idiopathic CD4(+) T-cell lymphocytopenia. Biol Aujourdhui, 2010, 204: 273-284.","journal-title":"Biol Aujourdhui"},{"key":"CITATION127","doi-asserted-by":"publisher","first-page":"e10248","DOI":"10.15252\/emmm.201810248","volume":"11","author":"Voet S","year":"2019","unstructured":"Voet S, Srinivasan S, Lamkanfi M, van Loo G. Inflammasomes in neuroinflammatory and neurodegenerative diseases. EMBO Mol Med, 2019, 11:","journal-title":"EMBO Mol Med"},{"key":"CITATION128","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3389\/fimmu.2019.00250","volume":"10","author":"Ritvo PG","year":"2019","unstructured":"Ritvo PG, Klatzmann D. Interleukin-1 in the response of follicular helper and follicular regulatory T cells. Front Immunol, 2019, 10:","journal-title":"Front Immunol"},{"key":"CITATION129","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1365-2141.2011.08794.x","volume":"155","author":"Mraz M","year":"2011","unstructured":"Mraz M, Zent CS, Church AK, Jelinek DF, Wu X, Pospisilova S, Ansell SM. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin \u03b1-4-\u03b2-1 (VLA-4) with natalizumab can overcome this resistance. Br J Haematology, 2011, 155: 53-64.","journal-title":"Br J Haematology"},{"key":"CITATION130","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1254\/jphs.92.7","volume":"92","author":"Nishibori M","year":"2003","unstructured":"Nishibori M, K. Takahashi H, Mori S. The regulation of ICAM-1 and LFA-1 interaction by autacoids and statins: a novel strategy for controlling inflammation and immune responses. J Pharmacol Sci, 2003, 92: 7-12.","journal-title":"J Pharmacol Sci"},{"key":"CITATION131","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40265-021-01553-7","volume":"81","author":"Gilreath J","year":"2021","unstructured":"Gilreath J, Lo M, Bubalo J. Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists. Drugs, 2021, 81: 1285-1305.","journal-title":"Drugs"},{"key":"CITATION132","doi-asserted-by":"publisher","first-page":"iv70","DOI":"10.1136\/ard.2005.042523","volume":"64","author":"Clark J","year":"2005","unstructured":"Clark J, Vagenas P, Panesar M, Cope AP. What does tumour necrosis factor excess do to the immune system long term?. Ann Rheumatic Dis, 2005, 64: iv70-iv76.","journal-title":"Ann Rheumatic Dis"},{"key":"CITATION133","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1055\/s-2000-13213","volume":"26","author":"Clauss M","year":"2000","unstructured":"Clauss M. Molecular biology of the VEGF and the VEGF receptor family. Semin Thromb Hemost, 2000, 26: 561-569.","journal-title":"Semin Thromb Hemost"},{"key":"CITATION134","doi-asserted-by":"publisher","first-page":"106221","DOI":"10.1016\/j.intimp.2020.106221","volume":"80","author":"Hosseini A","year":"2020","unstructured":"Hosseini A, Gharibi T, Marofi F, Babaloo Z, Baradaran B. CTLA-4: from mechanism to autoimmune therapy. Int Immunopharmacol, 2020, 80:","journal-title":"Int Immunopharmacol"},{"key":"CITATION135","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1182\/blood.V128.22.763.763","volume":"128","author":"Daver N","year":"2016","unstructured":"Daver N, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Jabbour EJ, Hendrickson S. Phase IB\/II study of nivolumab in combination with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML). Blood, 2016, 128:","journal-title":"Blood"},{"key":"CITATION136","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1182\/blood-2018-99-120157","volume":"132","author":"Daver NG","year":"2018","unstructured":"Daver NG, Garcia-Manero G, Basu S, Cortes JE, Ravandi F, Kadia TM, Konopleva MY. Safety, efficacy, and biomarkers of response to azacitidine (AZA) with nivolumab (Nivo) and AZA with nivo and ipilimumab (Ipi) in relapsed\/refractory acute myeloid leukemia: a non-randomized, phase 2 study. Blood, 2018, 132:","journal-title":"Blood"},{"key":"CITATION137","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/NEJMoa1601202","volume":"375","author":"Davids MS","year":"2016","unstructured":"Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, Lukez AP. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med, 2016, 375: 143-153.","journal-title":"N Engl J Med"},{"key":"CITATION138","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1182\/blood-2008-07-168468","volume":"113","author":"Bashey A","year":"2009","unstructured":"Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, Lowy I. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood, 2009, 113: 1581-1588.","journal-title":"Blood"},{"key":"CITATION139","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1182\/blood-2019-128178","volume":"134","author":"Borate U","year":"2019","unstructured":"Borate U, Esteve J, Porkka K, Knapper S, Vey N, Scholl S, Garcia-Manero G. Phase ib study of the anti-TIM-3 antibody MBG453 in combination with decitabine in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Blood, 2019, 134:","journal-title":"Blood"},{"key":"CITATION140","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/mt.2013.154","volume":"21","author":"Ritchie DS","year":"2013","unstructured":"Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K, Chen K. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther, 2013, 21: 2122-2129.","journal-title":"Mol Ther"},{"key":"CITATION141","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/mt.2014.164","volume":"23","author":"Wang Q","year":"2015","unstructured":"Wang Q, Wang Y, Lv H, Han Q, Fan H, Guo B, Wang L. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther, 2015, 23: 184-191.","journal-title":"Mol Ther"},{"key":"CITATION142","unstructured":"Tang X, Yang L, Li Z, Nalin AP, Dai H, Xu T, Yin J,                         et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.                                                      Am J Cancer Res                          2018, 8: 1083\u20131089."},{"key":"CITATION143","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2018-99-110579","volume":"132","author":"Liu F","year":"2018","unstructured":"Liu F, Cao Y, Pinz K, Ma Y, Wada M, Chen K, Ma G. First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial. Blood, 2018, 132:","journal-title":"Blood"},{"key":"CITATION144","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1182\/blood-2016-08-735365","volume":"129","author":"Leong SR","year":"2017","unstructured":"Leong SR, Sukumaran S, Hristopoulos M, Totpal K, Stainton S, Lu E, Wong A. An anti-CD3\/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia. Blood, 2017, 129: 609-618.","journal-title":"Blood"},{"key":"CITATION145","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/blood-2018-99-109762","volume":"132","author":"Ravandi F","year":"2018","unstructured":"Ravandi F, Stein AS, Kantarjian HM, Walter RB, Paschka P, Jongen-Lavrencic M, Ossenkoppele GJ. A Phase 1 first-in-human study of AMG 330, an anti-CD33 bispecific T-cell engager (BiTE\u00ae) antibody construct, in relapsed\/refractory acute myeloid leukemia (R\/R AML). Blood, 2018, 132:","journal-title":"Blood"},{"key":"CITATION146","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1182\/blood-2018-99-111529","volume":"132","author":"Westervelt P","year":"2018","unstructured":"Westervelt P, Roboz GJ, Cortes JE, Kantarjian HM, Lee S, Rettig MP, Han TH. Phase 1 first-in-human trial of AMV564, a bivalent bispecific (2x2) CD33\/CD3 T-cell engager, in patients with relapsed\/refractory acute myeloid leukemia (AML). Blood, 2018, 132:","journal-title":"Blood"},{"key":"CITATION147","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1182\/blood-2019-127977","volume":"134","author":"Subklewe M","year":"2019","unstructured":"Subklewe M, Stein A, Walter RB, Bhatia R, Wei AH, Ritchie D, B\u00fccklein V. Preliminary results from a phase 1 first-in-human study of AMG 673, a novel half-life extended (HLE) anti-CD33\/CD3 biTE\u00ae (bispecific T-cell engager) in patients with relapsed\/refractory (R\/R) acute myeloid leukemia (AML). Blood, 2019, 134:","journal-title":"Blood"},{"key":"CITATION148","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1182\/blood-2018-99-119786","volume":"132","author":"Ravandi F","year":"2018","unstructured":"Ravandi F, Bashey A, Foran JM, Stock W, Mawad R, Blum W, Saville MW. Complete responses in relapsed\/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of xmAb14045, a CD123 x CD3 T cell-engaging bispecific antibody: initial results of a phase 1 study. Blood, 2018, 132:","journal-title":"Blood"},{"key":"CITATION149","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1182\/blood-2018-99-117085","volume":"132","author":"Uy GL","year":"2018","unstructured":"Uy GL, Rettig MP, Vey N, Godwin J, Foster MC, Rizzieri DA, Arellano ML. Phase 1 cohort expansion of flotetuzumab, a CD123\u00d7CD3 bispecific dart\u00ae protein in patients with relapsed\/refractory acute myeloid leukemia (AML). Blood, 2018, 132:","journal-title":"Blood"},{"key":"CITATION150","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"Kantarjian H","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med, 2017, 376: 836-847.","journal-title":"N Engl J Med"},{"key":"CITATION151","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","volume":"95","author":"Loffler A","year":"2000","unstructured":"Loffler A, Kufer P, Lutterbu\u0308se R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmu\u0308ller G. A recombinant bispecific single-chain antibody, CD19\u2009\u00d7\u2009CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood, 2000, 95: 2098-2103.","journal-title":"Blood"},{"key":"CITATION152","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/ejh.12862","volume":"98","author":"Thota S","year":"2017","unstructured":"Thota S, Advani A. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia. Eur J Haematol, 2017, 98: 425-434.","journal-title":"Eur J Haematol"},{"key":"CITATION153","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/S1470-2045(19)30823-X","volume":"21","author":"Singh AK","year":"2020","unstructured":"Singh AK, McGuirk JP. CAR T cells: continuation in a revolution of immunotherapy. Lancet Oncol, 2020, 21: e168-e178.","journal-title":"Lancet Oncol"},{"key":"CITATION154","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","volume":"130","author":"Gomes-Silva D","year":"2017","unstructured":"Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, Rouce RH. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood, 2017, 130: 285-296.","journal-title":"Blood"},{"key":"CITATION155","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1038\/leu.2017.8","volume":"31","author":"Chen KH","year":"2017","unstructured":"Chen KH, Wada M, Pinz KG, Liu H, Lin KW, Jares A, Firor AE. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia, 2017, 31: 2151-2160.","journal-title":"Leukemia"},{"key":"CITATION156","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-021-01077-3","volume":"14","author":"Hou JZ","year":"2021","unstructured":"Hou JZ, Ye JC, Pu JJ, Liu H, Ding W, Zheng H, Liu D. Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting. J Hematol Oncol, 2021, 14:","journal-title":"J Hematol Oncol"},{"key":"CITATION157","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41408-021-00467-7","volume":"11","author":"Timofeeva N","year":"2021","unstructured":"Timofeeva N, Gandhi V. Ibrutinib combinations in CLL therapy: scientific rationale and clinical results. Blood Cancer J, 2021, 11:","journal-title":"Blood Cancer J"},{"key":"CITATION158","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1182\/blood-2014-07-587360","volume":"124","author":"Seiffert M","year":"2014","unstructured":"Seiffert M. Lenalidomide, an antiproliferative CLL drug. Blood, 2014, 124: 1545-1546.","journal-title":"Blood"},{"key":"CITATION159","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1002\/ajh.25595","volume":"94","author":"Hallek M","year":"2019","unstructured":"Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol, 2019, 94: 1266-1287.","journal-title":"Am J Hematol"},{"key":"CITATION160","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1186\/s13063-017-2138-6","volume":"18","author":"Collett L","year":"2017","unstructured":"Collett L, Howard DR, Munir T, McParland L, Oughton JB, Rawstron AC, Hockaday A. Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. Trials, 2017, 18:","journal-title":"Trials"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/engine.scichina.com\/doi\/pdf\/0052883756D64ED7871C4F497CFBBD54","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/engine.scichina.com\/doi\/10.3724\/abbs.2023101","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/engine.scichina.com\/doi\/pdf\/0052883756D64ED7871C4F497CFBBD54","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T03:21:05Z","timestamp":1688527265000},"score":1,"resource":{"primary":{"URL":"https:\/\/engine.scichina.com\/doi\/10.3724\/abbs.2023101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":160,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,2]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.3724\/abbs.2023101","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,1]]}}}